AndreaBozzo/ceres-open-data-index huggingface dataset:
Patent AT-E400126-T1: [Translated] CASCADING NETWORK DEVICE WITH A CONTENT BASED MESSAGE DISTRIBUTOR FOR SCALING

Various embodiments directed to a cascading a network apparatus for scalability. In one or more embodiments, an apparatus may comprise an extensible markup language (XML) device to receive a content based message comprising a header, a destination Internet Protocol (IP) address, and destination port number via one or more received packets. The XML device may have a configuration and process the content based message only if the received packets comprise a destination IP address and destination port number that match the configuration of the XML device. The XML device may forward processed content based message via one or more packets that differ from the received packets. Other embodiments are described and claimed.
Compound 530546: 3-Cyclopentylpropionic acid, tridecyl ester

Chemical compound data from PubChem database. IUPAC Name: tridecyl 3-cyclopentylpropanoate. Molecular Formula: C21H40O2. Molecular Weight: 324.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
2010 CMHS Uniform Reporting System (URS) Output Tables for New Hampshire

Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for 2010. The Uniform Reporting System (URS) is a state and national reporting system collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
NNDSS - TABLE 1KK. Vancomycin-intermediate Staphylococcus aureus to Varicella morbidity

NNDSS - TABLE 1KK. Vancomycin-intermediate Staphylococcus aureus to Varicella morbidity – 2022. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents.

Notes:

•	These are weekly cases of selected infectious national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables available at https://www.cdc.gov/nndss/data-statistics/index.html. Cases reported by state health departments to CDC for weekly publication are subject to ongoing revision of information and delayed reporting. Therefore, numbers listed in later weeks may reflect changes made to these counts as additional information becomes available. Case counts in the tables are presented as published each week. See also Guide to Interpreting Provisional and Finalized NNDSS Data at https://www.cdc.gov/nndss/docs/Readers-Guide-WONDER-Tables-20210421-508.pdf.
• Notices, errata, and other notes are available in the Notice To Data Users page at https://wonder.cdc.gov/nndss/NTR.html.
•	The list of national notifiable infectious diseases and conditions and their national surveillance case definitions are available at https://ndc.services.cdc.gov/. This list incorporates the Council of State and Territorial Epidemiologists (CSTE) position statements approved by CSTE for national surveillance.

Footnotes:

*Case counts for reporting years 2021 and 2022 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://www.cdc.gov/nndss/docs/Readers-Guide-WONDER-Tables-20210421-508.pdf.
†Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data).
U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data.
-: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.
NN: Not nationally notifiable — This condition was not designated as being nationally notifiable.
NP: Nationally notifiable but not published.
NC: Not calculated — There is insufficient data available to support the calculation of this statistic.
Cum: Cumulative year-to-date counts.
Max: Maximum — Maximum case count during the previous 52 weeks.
Patent AT-E400293-T1: [Translated] SIGNAL-1/SIGNAL-2 BIFUNCTIONAL PEPTIDE INHIBITORS

A novel peptide sequence having the general formula AB wherein each of A and B represent a chain of amino acid residues and wherein said A chain is capable of binding with a mojor histocompatibility comples on an antigen presenting cell, and wherein said B chain is capable of binding wiht a Signal-2 receptor on an antigen presenting cell. Preferred forms of the peptide sequence further include and Y chain positioned intermediate the A chain and the B chain. Moreover, preferred forms include and A chain which has at least about 10% sequence homology with a Signal-1 moiety, or is a peptidomimetic of a Signal-1 moiety, said B chain has at least 10% sequence homology with a Signal-2 receptor moiety, said B chain has at least 10% sequence homology with a Signal-2 receptor moiety, or is a peptidomimetic of a Signal-2 receptpr moiety, and wherein the X chain has at least one amino acid residue, or is a peptidomimetic of that amino acid residue. Advantageously, the movel peptide sequence is capable of shifting a type-1 immune response to a type-2 immune response or from a type-2 immune response to a type-1 immune response.
Patent AT-E399891-T1: [Translated] WATER-DISPPERSIBLE AND MULTI-COMPONENT FIBERS MADE OF SULFOPOLYESTERS

Disclosed are water-dispersible fibers derived from sulfopolyesters having a Tg of at least 25°C. The fibers may contain a single sulfopolyester or a blend of a sulfopolyester with a water-dispersible or water-nondispersible polymer. Also disclosed are multicomponent fibers comprising a water dispersible sulfopolyester having a Tg of at least 57°C and a water nondispersible polymer. The multicomponent fibers may be used to produce microdenier fibers. Fibrous articles may be produced from the water-dispersible fibers, multicomponent fibers, and microdenier fibers. The fibrous articles include waterdispersible and microdenier nonwoven webs, fabrics, and multilayered articles such as wipes, gauze, tissue, diapers, panty liners, sanitary napkins, bandages, and surgical dressings. Also disclosed is a process for water-dispersible fibers, nonwoven fabrics, and microdenier webs. The fibers and fibrous articles have further applications in flushable personal care and cleaning products, disposable protective outerwear, and laminating binders.
NNDSS - TABLE 1EE. Salmonella Paratyphi infection to Salmonellosis (excluding Salmonella Typhi infection and Salmonella Paratyphi infection)

NNDSS - TABLE 1EE. Salmonella Paratyphi infection to Salmonellosis (excluding Salmonella Typhi infection and Salmonella Paratyphi infection) – 2022. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents.

Notes:

•	These are weekly cases of selected infectious national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables available at https://www.cdc.gov/nndss/data-statistics/index.html. Cases reported by state health departments to CDC for weekly publication are subject to ongoing revision of information and delayed reporting. Therefore, numbers listed in later weeks may reflect changes made to these counts as additional information becomes available. Case counts in the tables are presented as published each week. See also Guide to Interpreting Provisional and Finalized NNDSS Data at https://www.cdc.gov/nndss/docs/Readers-Guide-WONDER-Tables-20210421-508.pdf.
• Notices, errata, and other notes are available in the Notice To Data Users page at https://wonder.cdc.gov/nndss/NTR.html.
•	The list of national notifiable infectious diseases and conditions and their national surveillance case definitions are available at https://ndc.services.cdc.gov/. This list incorporates the Council of State and Territorial Epidemiologists (CSTE) position statements approved by CSTE for national surveillance.

Footnotes:

*Case counts for reporting years 2021 and 2022 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://www.cdc.gov/nndss/docs/Readers-Guide-WONDER-Tables-20210421-508.pdf.
†Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data).
U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data.
-: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.
NN: Not nationally notifiable — This condition was not designated as being nationally notifiable.
NP: Nationally notifiable but not published.
NC: Not calculated — There is insufficient data available to support the calculation of this statistic.
Cum: Cumulative year-to-date counts.
Max: Maximum — Maximum case count during the previous 52 weeks.
Miami - Fort Lauderdale Div: Drug-Related Emergency Department Visits, 2008-2011 - Adverse Reactions

Excel file with estimates, rates, relative standard errors, trends and confidence intervals, covering 2008-2011 for emergency department visits involving adverse reactions in the Miami metropolitan area, Fort Lauderdale division. It includes ED visits in which an adverse health consequence (e.g., side effects or an allergic reaction) resulted when taking prescription drugs, over-the-counter medications, or dietary supplements as prescribed or recommended.  This analytic category does not include drug misuse or abuse.File includes data for over 500 drugs, including illicit drugs, prescription and over-the-counter medications, dietary supplements, inhalants and alcohol.  Includes total visits, gender, age group, race/ethnicity, outcome of visit, drug combinations, number of drugs involved in visit, drug frequency, and drugs confirmed by toxicology.Additional detail is provided for illicit drugs, psychotherapeutic drugs, central nervous system (CNS) drugs, respiratory drugs and cardiovascular drugs.
IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis

The origin and role of IL-17, a T-cell derived cytokine, in cartilage and bone destruction during rheumatoid arthritis (RA) remain to be clarified. In human ex vivo models, addition of IL-17 enhanced IL-6 production and collagen destruction, and inhibited collagen synthesis by RA synovium explants. On mouse cartilage, IL-17 enhanced cartilage proteoglycan loss and inhibited its synthesis. On human RA bone explants, IL-17 also increased bone resorption and decreased formation. Addition of IL-1 in these conditions increased the effect of IL-17. Blocking of bone-derived endogenous IL-17 with specific inhibitors resulted in a protective inhibition of bone destruction. Conversely, intra-articular administration of IL-17 into a normal mouse joint induced cartilage degradation. In conclusion, the contribution of IL-17 derived from synovium and bone marrow T cells to joint destruction suggests the control of IL-17 for the treatment of RA.
Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy

Purpose
          The present study aimed at evaluating the efficacy of Raltitrexed, a specific thymidilate synthase inhibitor, in patients with advanced colorectal cancer (ACC) in relapse (>8 weeks) after a prior response or disease stabilization to first-line chemotherapy combination with lrinotecan+5-Fluorouracil (5-FU)+Leucovorin (LV).
        
        
          Methods
          Twenty-five patients with metastatic ACC entered; 17 males/8 females, median age 61 (range: 47–70), median Karnovsky PS: 80 (70–90), and sites of metastases; liver: 21, lung: 4, lymph nodes: 7, peritoneal: 5 and a life expectancy of at least 3 months, were entered in the present pilot study. All patients had progressed after prior chemotherapy with lrinotecan+5-FU+LV. Raltitrexed was administered at a dose of 3 mg/m2 i.v. every 21 days.
        
        
          Results
          Three patients (12%) achieved a partial response (PR), 8 (32%) had stable disease (SD), and the remaining 14 (56%) developed progressive disease (PD). Median time-to-progression (TTP) was 5.5 months (range, 2–8.5), and median overall survival (OS) 8 months (range, 4.0–12.5). Toxicity was generally mild; it consisted mainly of myelosuppression; neutropenia grade 1–2: 52%-grade 3: 28%, and anemia grade 1–2 only: 36%. Mild mucositis grade 1–2 occured in 13.5% of patients and was the principal non-hematologic toxicity.
        
        
          Conclusion
          Response to treatment with Raltitrexed is limited in patients with ACC failing after an initial response or non-progression to the weekly lrinotecan+5-FU+LV combination. However, it appears that a limited number of patients with PR/SD may derive clinical benefit, but final proof would require a randomized study.
Compound 526836: 10-Hydroxy-heptadecanoic acid, methyl ester, tBDMS ether

Chemical compound data from PubChem database. IUPAC Name: methyl 10-[tert-butyl(dimethyl)silyl]oxyheptadecanoate. Molecular Formula: C24H50O3Si. Molecular Weight: 414.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Bupivacaine hydrochloride

Bupivacaine Hydrochloride is a prescription local anesthetic used to numb specific areas of the body during medical procedures or surgeries. Manufactured by Hikma Pharmaceuticals USA Inc., it comes in preservative-free injectable forms at strengths of 0.25%, 0.5%, and 0.75%, administered via epidural, infiltration, intracaudal, perineural, or retrobulbar routes. This information was generated using AI and is provided for informational and research purposes only.
Cyclobenzaprine hydrochloride

Cyclobenzaprine Hydrochloride is a prescription muscle relaxant used to relieve muscle spasms and pain from injuries or conditions like back strain. Available as oral tablets in 5 mg, 7.5 mg, and 10 mg strengths, it's a generic version manufactured by Advagen Pharma Limited and others. This information was generated using AI and is provided for informational and research purposes only.
Hospital Inpatient Discharges (SPARCS De-Identified): Patient Safety Indicators (PSI) Area Measures by Patient County: Beginning 2009

The datasets contain hospital discharges counts (numerators, denominators, volume counts), observed, expected and risk-adjusted rates with corresponding 95% confidence intervals for Patient Safety Indicators generated using methodology developed by Agency for Healthcare Research and Quality (AHRQ).

The PSIs are a set of indicators providing information on potential in hospital complications and adverse events following surgeries, procedures, and childbirth. The PSIs were developed by AHRQ after a comprehensive literature review, analysis of ICD-9-CM codes, review by a clinician panel, implementation of risk adjustment, and empirical analyses.

All PSI measures were calculated using Statewide Planning and Research Cooperative System (SPARCS) inpatient data beginning 2009.  US Census data files provided by AHRQ were used to derive denominators for county level (area level) PSI measures.

The mortality, volume and utilization measures PSIs are presented by hospital as rates or counts. Area-level measures are presented by county as rates.
Manipulation of gene expression by an ecdysone-inducible gene switch in tumor xenografts

Background
          Rapid, robust and reversible induction of transgene expression would significantly facilitate cancer gene therapy as well as allow the in vivo functional study of newly discovered genes in tumor formation and progression. The popularity of the ecdysone inducible gene switch system has led us to investigate whether such a system can successfully regulate gene expression in a syngeneic tumor system in vivo.
        
        
          Results
          MBT-2 and Panc02 carcinoma cells were transfected with components of a modification of the ecdysone switch system driving firefly luciferase (F-Luc). In vitro luciferase expression ± ecdysone analog GS-E indicated a robust induction with minimal baseline activity and complete decay after 24 hours without drug. In vitro selection of MBT-2 transfected cell clones which had complete absence of F-Luc expression in the absence of stimulation but which expressed this gene at high levels in response to GS-E were chosen for in vivo evaluation. Tumors from engineered MBT-2 cells were grown to 5 mm in diameter prior to GS-E administration, animals euthanized and tumors removed at 6, 12 and 24 hours after GS-E administration and assayed for F-Luc activity. GS-E resulted in a maximal induction of F-Luc activity at 6 hours in tumor tissue with almost complete reversion to control levels by 12 hours.
        
        
          Conclusions
          This study is the first demonstration that robust and reversible transgene expression in tumors is feasible using the ecdysone system, allowing future rapid in vivo functional characterization of gene function or gene therapy applications.
Weekly Counts of Death by Jurisdiction and Select Causes of Death

Effective September 27, 2023, this dataset will no longer be updated. Similar data are accessible from wonder.cdc.gov.

This visualization provides weekly data on the number of deaths by jurisdiction of occurrence and cause of death. Counts of deaths in more recent weeks can be compared with counts from earlier years to determine if the number is higher than expected. Selected causes of death are shown, based on analyses of the most prevalent comorbid conditions reported on death certificates where COVID-19 was listed as a cause of death (see https://www.cdc.gov/nchs/nvss/vsrr/covid_weekly/index.htm#Comorbidities). Cause of death counts are based on the underlying cause of death, and presented for Respiratory diseases, Circulatory diseases, Malignant neoplasms, and Alzheimer disease and dementia. Estimated numbers of deaths due to these other causes of death could represent misclassified COVID-19 deaths, or potentially could be indirectly related to COVID-19 (e.g., deaths from other causes occurring in the context of health care shortages or overburdened health care systems). Deaths with an underlying cause of death of COVID-19 are not included in these estimates of deaths due to other causes. Deaths due to external causes (i.e. injuries) or unknown causes are excluded. For more detail, see the Technical Notes.
Compound 527579: Pentane, 1-iodo-3,3-dimethyl

Chemical compound data from PubChem database. IUPAC Name: 1-iodo-3,3-dimethylpentane. Molecular Formula: C7H15I. Molecular Weight: 226.1. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Insulin: a wonder drug in the critically ill?

Stress hyperglycaemia is a common event in acute critical illness. There is increasing evidence that maintaining normoglycaemia and treatment with insulin (or with glucose–insulin–potassium [GIK]), even in non-diabetic persons, is helpful in limiting organ damage after myocardial infarction, stroke, traumatic brain injury and other conditions, even though the conditions may be accompanied by insulin resistance. A landmark study now suggests that maintaining normoglycaemia with intensive insulin treatment in a heterogeneous population of critically ill patients decreases morbidity and mortality. The potential mechanisms that underlie such a beneficial effect are discussed.
Compound 530189: Trimethyl-(6-trimethylsilyloxypurin-7-yl)silane

Chemical compound data from PubChem database. IUPAC Name: trimethyl-(6-trimethylsilyloxypurin-7-yl)silane. Molecular Formula: C11H20N4OSi2. Molecular Weight: 280.47. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
NCHS Research and Development Survey (RANDS) Round 1 during COVID-19 non-probability sampled Restricted File

The Research and Development Survey (RANDS) is a series of cross-sectional surveys from probability-sampled commercial survey panels. As part of a special iteration of RANDS that focuses on COVID-19, RANDS during COVID-19 Round 1 is the first round of a three-round survey. In addition to the probability sample in RANDS during COVID-19 Round 1, the questionnaire was administered to the Dynata non-probability online opt-in sample by NORC at the University of Chicago (NORC) from June 9, 2020 to June 30, 2020. The RANDS during COVID-19 Round 1 Non-Probability Sample does not have a known survey sampling design and cannot be used to produce nationally or sub-nationally representative estimates.
Patent AT-E401420-T1: [Translated] DNA DETECTION USING PRIMERS WHICH HYBRIDISE WITH NON-FRAGMENTED DNA

The present invention provides a method of detecting non-apoptotic DNA in clinical samples. In particular there is provided a novel screening methodology for the detection of colorectal carcinoma. Cancer results from genetic mutations which result in uncontrolled and unregulated cell growth. Apoptosis does not occur in cancerous cells and thus the DNA remains unfragmented. Colorectal cancer results from mutations which occur in varying sites of the DNA. Accordingly there is no ubiquitous marker specific to colorectal tumour cells. The present invention provides the finding that the presence of specific fragments of DNA can be used to diagnose cancer irrespective of the point of DNA mutation. The method includes the step of obtaining a suitable sample, extracting the DNA therefrom and then amplifying and separating the fragments by electrophoresis in order to detect the presence of banding which is indicative of non-fragmented DNA derived from cancerous cells.
Compound 526098: Tetradecanoic acid, 8-methyl, trimethylsilyl ester

Chemical compound data from PubChem database. IUPAC Name: trimethylsilyl 8-methyltetradecanoate. Molecular Formula: C18H38O2Si. Molecular Weight: 314.6. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.